These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 37615334)

  • 1. Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions.
    Rajapakse J; Khatiwada S; Akon AC; Yu KL; Shen S; Zekry A
    Gut Microbes; 2023 Dec; 15(2):2240031. PubMed ID: 37615334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma.
    Song Y; Lau HC; Zhang X; Yu J
    Cancer Biol Med; 2023 Dec; 21(2):144-62. PubMed ID: 38148326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gut microbiota - A vehicle for the prevention and treatment of hepatocellular carcinoma.
    Beyoğlu D; Idle JR
    Biochem Pharmacol; 2022 Oct; 204():115225. PubMed ID: 35998677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
    Golonka RM; Vijay-Kumar M
    Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota: A new piece in understanding hepatocarcinogenesis.
    Zhou A; Tang L; Zeng S; Lei Y; Yang S; Tang B
    Cancer Lett; 2020 Apr; 474():15-22. PubMed ID: 31917160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal Microbiota Transplantation in NAFLD Treatment.
    Abenavoli L; Maurizi V; Rinninella E; Tack J; Di Berardino A; Santori P; Rasetti C; Procopio AC; Boccuto L; Scarpellini E
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363516
    [No Abstract]   [Full Text] [Related]  

  • 10. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings.
    Das BK
    APMIS; 2022 Dec; 130(12):719-740. PubMed ID: 36321381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Gut Microbial Metabolites in the Pathogenesis of Primary Liver Cancers.
    Pallozzi M; De Gaetano V; Di Tommaso N; Cerrito L; Santopaolo F; Stella L; Gasbarrini A; Ponziani FR
    Nutrients; 2024 Jul; 16(14):. PubMed ID: 39064815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Benedé-Ubieto R; Cubero FJ; Nevzorova YA
    Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
    Ezzaidi N; Zhang X; Coker OO; Yu J
    Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
    Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
    Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma.
    Shen S; Khatiwada S; Behary J; Kim R; Zekry A
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling.
    Li Z; Zhang Y; Hong W; Wang B; Chen Y; Yang P; Zhou J; Fan J; Zeng Z; Du S
    Gut Microbes; 2022; 14(1):2119055. PubMed ID: 36093568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Microbiome and Liver Cancer.
    Myojin Y; Greten TF
    Cancer J; 2023 Mar-Apr 01; 29(2):57-60. PubMed ID: 36957974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
    Jiang JW; Chen XH; Ren Z; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.